TABLE 2.
Trap mean values.
| Mean TRAP (μmol/L) ± sd (range) | |||
|---|---|---|---|
| All | Men | Women | |
| Overall | 1137 ± 305 (241–1735) | 1320 ± 293 (241–1735) | 1082 ± 288 (266–1713) |
| Age (years) | |||
| 18–40 | 1121 ± 337 (241–1735) | 1301 ± 430 (241–1735) | 1072 ± 295 (409–11637) |
| 41–72 | 1149 ± 281 (266–1713) | 1331 ± 179 (1017–1656) | 1089 ± 284 (266–1713) |
| Type of MS | |||
| RRMS | 1120 ± 311 (241–1735) | 1307 ± 329 (241–1735) | 1070 ± 288 (266–1681) |
| SPMS | 1229 ± 265 (761–1713) | 1361 ± 131 (1183–1558) | 1151 ± 299 (761–1713) |
| PPMS | 1183 ± 297 (973–1393) | – | 1183 ± 297 (973–1393) |
| Relapses in a 2‐year period | |||
| Relapse | 1113 ± 258 (543–1634) | 1324 ± 199 (1017–1634) | 1047 ± 240 (543–1459) |
| No relapse | 1151 ± 329 (241–1735) | 1318 ± 338 (241–1735) | 1100 ± 312 (266–1713) |
| EDSS score | |||
| EDSS ≥ 3 | 1127 ± 320 (241–1713) | 1290 ± 330 (241–1656) | 1065 ± 296 (293–1713) |
| EDSS < 3 | 1150 ± 288 (266–1735) | 1375 ± 213 (1084–1735) | 1101 ± 280 (266–1681) |
| Smoking | |||
| Smokers | 1189 ± 274 (543–1735) | 1333 ± 312 (1084–1735) | 1158 ± 265 (543–1637) |
| Non smokers | 1160 ± 294 (266–1713) | 1430 ± 123 (1209–1659) | 1083 ± 283 (266–1713) |
| MRI lesions in a 2‐year period | |||
| No new lesions | 1121 ± 289 (293–1656) | 1316 ± 212 (1074–1656) | 1054 ± 285 (293–1505) |
| New T2 and Gd lesions | 1110 ± 295 (241–1459) | 901 ± 610 (241–1444) | 1155 ± 195 (721–1459) |
| New T2 lesions | 1096 ± 303 (241–1634) | 1234 ± 480 (241–1634) | 1054 ± 229 (543–1459) |
| DMT | |||
| No medication | 1255 ± 268 (761–1713) | 1426 ± 152 (1209–1634) | 1190 ± 276 (761–1713) |
| Interferon and glatiramer acetate | 1159 ± 294 (241–1735) | 1279 ± 334 (241–1735) | 1113 ± 267 (266–1681) |
| Natalizumab | 991 ± 294 (543–1539) | 1337 ± 280 (1017–1539) | 926 ± 255 (543–1325) |
| Fingolimod | 982 ± 473 (293–1459) | – | 982 ± 473 (293–1459) |
| Azathioprine | 968 ± 191 (718–1153) | – | 968 ± 191 (718–1153) |
Abbreviations: DMT, disease modifying therapy; EDSS, expanded disability status scale; MS, multiple sclerosis; MRI, magnetic resonance imaging; PPMS, primary progressive MS; RRMS, relapsing‐remitting MS; SPMS, secondary progressive MS.